Hysingla Er generic
Hysingla Er is an analgesic drug owned by Purdue Pharma Lp. The active ingredient in Hysingla Er is hydrocodone bitartrate. The drug was authorised for market use on 20 November, 2014. It is available in tablet, extended release;oral dosage forms and has a total of 24 drug patents, out of which 5 have already expired.
When will Hysingla Er generic be available?
The generic versions of Hysingla Er are expected to be released after 21 December, 2031. This is due to the expiration of the last patent (US8808740 titled 'Encased tamper resistant controlled release dosage forms') on the same date.
Hysingla Er uses
Hysingla Er is used for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. hydrocodone bitartrate, the active ingredient in Hysingla Er, helps achieve this effectiveness.
Hysingla Er patent expiration
Hysingla Er holds 24 drug patents in total. Five of these have expired, and the last patent is set to expire on 21 December, 2031. The majority of these patents are related to 'Tamper resistant dosage forms' and 'Abuse-proofed dosage form'. After the expiration of the last patent, Hysingla Er generic will be available. Below are the details of the patent: